Results 91 to 100 of about 21,847 (205)

Proteome‐Wide Target Identification Using Reactive Metallo‐Scaffolds (r‐mS): A Platform for Metallodrug Discovery

open access: yesAngewandte Chemie, Volume 138, Issue 38, 14 September 2026.
Re‐envisioning the Ligandable Proteome: Reactive Metallo‐Scaffolds (r‐mS) combine non‐covalent protein engagement by a metallo‐scaffold with covalent cysteine capture through a tethered chloroacetamide warhead. Chemoproteomic profiling reveals unique enzyme engagement including ligases, kinases and methyltransferases, highlighting opportunities for ...
Jessica E. Waters   +15 more
wiley   +2 more sources

Cardiovascular Toxicity Associated With Bispecific Antibodies in Hematological Malignancies: A Comprehensive Pharmacovigilance Analysis

open access: yesAmerican Journal of Hematology, Volume 101, Issue 10, Page 2546-2556, October 2026.
ABSTRACT Cardiovascular adverse events (CVAEs) associated with bispecific T‐cell engaging antibodies (BsAbs) have not been systematically investigated across approved agents. In this disproportionality analysis of FAERS (December 2014–September 2025), reports listing BsAbs as the primary suspected drug (n = 7647) were compared with all other drugs in ...
Malak Munir   +9 more
wiley   +1 more source

Revisiting the Carbon Footprint of Single‐Use Technologies in Biomanufacturing: A Bottom‐Up Analysis Reveals a Paradigm Shift

open access: yesBiotechnology and Bioengineering, Volume 123, Issue 10, Page 2802-2814, October 2026.
ABSTRACT The biopharmaceutical industry increasingly relies on single‐use technologies (SUT) for operational flexibility. For a long time, SUT was considered more sustainable than stainless‐steel (SST) systems due to water and energy savings. This study re‐evaluates this paradigm via a detailed bottom‐up analysis of the SUT carbon footprint at the 2000 
Jan Reiners   +4 more
wiley   +1 more source

To Treat or Not to Treat: Navigating Early‐Stage CLL in the Era of Targeted Therapy

open access: yesEuropean Journal of Haematology, Volume 117, Issue 4, Page 750-766, October 2026.
ABSTRACT Chronic lymphocytic leukemia (CLL) is most frequently diagnosed at early, asymptomatic stages (Rai 0/Binet A), in which a watch‐and‐wait strategy remains the standard of care, based on historical trials demonstrating no overall survival benefit from early treatment.
Enrica Antonia Martino   +16 more
wiley   +1 more source

Extranodal Marginal Zone Lymphoma: Integrating Etiology, Microenvironment, and Genetics Into Clinical Decision‐Making

open access: yesEuropean Journal of Haematology, Volume 117, Issue 4, Page 849-863, October 2026.
ABSTRACT Extranodal marginal zone lymphoma (EMZL) represents a unique paradigm among indolent B‐cell neoplasms, in which lymphomagenesis is frequently driven by chronic antigenic stimulation within tissue‐specific microenvironments. Persistent infectious or autoimmune triggers promote the development of ectopic lymphoid tissue and sustain B‐cell ...
Mamdouh Skafi   +15 more
wiley   +1 more source

Building an Interleukin‐10‐Producing Identity: How B Cells Acquire Interleukin‐10 Competence and How Plasma Cell Differentiation Consolidates This Program

open access: yesImmunological Reviews, Volume 343, Issue 1, October 2026.
ABSTRACT Interleukin (IL)‐10‐producing B cells represent an archetype for the regulatory functions of B cells. Here, we review the cell‐surface receptors and transcriptional regulators that control IL‐10 expression in B cells and enable their regulatory function in vivo.
Bui Thi Cuc   +4 more
wiley   +1 more source

Efficacy and Safety Profile of a Rituximab, Methotrexate, and Thiotepa‐Based Regimen in Newly Diagnosed Primary CNS Lymphoma

open access: yesInternational Journal of Cancer, Volume 159, Issue 6, Page 1499-1509, 15 September 2026.
Primary central nervous system diffuse large B‐cell lymphoma (PCNS‐DLBCL) lacks an optimal first‐line induction strategy, particularly for older patients and those ineligible for intensive consolidation. In this retrospective cohort of 36 newly diagnosed patients, the rituximab + methotrexate + thiotepa (RMT) regimen as first‐line induction achieved ...
Haotian Wang   +10 more
wiley   +1 more source

Inhibition of bruton’s tyrosine kinase directly alleviates pathogenic CD4+ T cell response via PPAR-γ signaling in autoimmune uveitis

open access: yesJournal of Neuroinflammation
Background Bruton’s tyrosine kinase (BTK), a key regulator of immune responses, has been extensively studied in B cells and innate immunocytes. Small-molecule BTK inhibitors (BTKi) have shown remarkable efficacy in multiple preclinical and clinical ...
Zhiqiang Xiao   +13 more
doaj   +1 more source

Chemoimmunotherapy‐associated CD20 (MS4A1) resistance mutations in Waldenström macroglobulinemia: Epitope disruption independent of expression with implications for CD20‐directed cellular therapies

open access: yes
HemaSphere, Volume 10, Issue 10, October 2026.
Alberto Guijosa   +18 more
wiley   +1 more source

BTK Inhibitor [PDF]

open access: yes, 2020
WANG XUEHAI   +27 more
openaire   +3 more sources

Home - About - Disclaimer - Privacy